JPX · 4503.T
Astellas Pharma Inc.
¥2,571+¥58 (+2.31%)
Astellas Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.37% below the high.
Loading market information…
JPX · 4569.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
KYORIN Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
KYORIN Holdings, Inc.’s forward annual dividend is ¥20 per share, paid semi-annual. The forward yield is 1.81% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
KYORIN Holdings, Inc.’s next earnings report is currently expected on Nov 9, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow KYORIN Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Tokyo, Japan, and founded in 1923, KYORIN Holdings, Inc. is a pharmaceutical enterprise engaged in the discovery, development, production, and worldwide distribution of both innovative prescription drugs and generic equivalents. Its diverse therapeutic catalog features medications such as Flutiform for asthma; Desalex, an antiallergic agent; and treatments like Beova, Uritos, and Imidafenacin KYORIN for overactive bladder. The company also offers Lasvic, a quinolone antibacterial; Pentasa for managing ulcerative colitis and Crohn's disease; Nasonex and Kipres for allergic rhinitis; and Mucodyne, a mucoregulating compound. Further pharmaceutical products include Montelukast KM, prescribed for bronchial asthma and allergic rhinitis. Beyond drugs, KYORIN Holdings markets specialized items like the GeneSoC real-time PCR system, disinfectant solutions such as Rubysta and Milton, over-the-counter remedies, diagnostic tools, industrial chemicals, and various reagents and intermediates. The company extends its services to include contract drug manufacturing and actively participates in early-stage research, including identifying and assessing candidate compounds, analyzing competitor technologies, and collecting data from clinical trials.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:02 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥2,571+¥58 (+2.31%)
Astellas Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.37% below the high.
¥3,012+¥23 (+0.77%)
Shionogi & Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
¥2,256+¥32 (+1.42%)
Ono Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.65% below the high.
¥1,885-¥61 (-3.11%)
Sumitomo Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.69% below the high.
¥3,436+¥18 (+0.53%)
Nippon Shinyaku Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.37% below the high.
¥3,805+¥90 (+2.42%)
Kissei Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 24.5% below the high.
¥3,830+¥30 (+0.79%)
Kaken Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 13.84% below the high.
